Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP)

NACompletedINTERVENTIONAL
Enrollment

833

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

October 15, 2021

Study Completion Date

November 30, 2021

Conditions
Covid19COVID-19 PneumoniaCOVID-19 Lower Respiratory InfectionCOVID-19 Acute Respiratory Distress SyndromeSARS-CoV2 InfectionSARS-CoV-2 Acute Respiratory Disease
Interventions
BEHAVIORAL

Antimicrobial stewardship prospective audit and feedback

Audits are performed on weekdays, less statutory holidays, by members of the antimicrobial stewardship team consisting of infectious disease or antimicrobial stewardship physicians or pharmacists. Verbal and written feedback will be provided in real-time. Initial prospective audit and feedback (PAF) will occur on the day of enrolment. Follow-up PAF will occur weekly (+/-3 days to account for weekends or statuary holidays) and ad-hoc if a new antibacterial is prescribed, until the primary end-point. Appropriateness will be assessed based on local clinical practice guidelines. Only antibacterials will be audited. Prescriptions will be excluded from PAF if they are single doses or discontinued prior to PAF. Prescriptions will be also be excluded from PAF and the final analysis if being used for surgical or medical prophylaxis.

Trial Locations (3)

T5R 4H5

Misericordia Community Hospital, Edmonton

T6G 2B7

University of Alberta Hospital, Edmonton

T6L 5X8

Grey Nuns Community Hospital, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

NCT04896866 - Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients (COVASP) | Biotech Hunter | Biotech Hunter